Advertisement

Topics

Antibe Therapeutics Inc. Company Profile

22:07 EST 11th December 2018 | BioPortfolio

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, which are chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and benefit from the predictable toxicity and effectiveness profiles of the base drug.


News Articles [722 Associated News Articles listed on BioPortfolio]

Antibe Therapeutics Enters Strategic Licensing Deal for Lead Drug in South Korea

NewsLicense includes C$13 million ($9.9 million) in non-dilutive milestone payments and a double-digit royalty to Antibe.Contribut

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal ...

Antibe Therapeutics Inc.Dan Legault, 416-473-4095Chief Executive Officerdan.legault@antibethera.com Read more...

Antibe Therapeutics (ATE) - Working towards a GI-safe NSAID drug

Edison Investment Research - Pharmaceutical & healthcare - Antibe Therapeutics: Antibe’s lead drug, ATB-346, combines a hydrogen sulfide (H2S)-emitting molecule with naproxen, an off-patent non-...

Antibe receives approval to start Phase llb trial of ATB-346

Antibe Therapeutics has received approval from Health Canada to begin the first part of its Phase llb clinical trial of...Read More... The post Antibe receives approval to start Phase llb trial of ATB...

Antibe Therapeutics Reports Full Phase 2B ATB-346 Trial Results

The trial, which originally finished in March 2018, reported that it met the primary endpoint of reduced ulceration rate, which was 42.1 percent for Naproxen patients versus 2.5 percent on ATB-346. Th...

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the...

Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29th for the fiscal qua...

Antibe Therapeutics Announces Results of Annual General and Special Meeting

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday. All...

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1283 Associated Companies listed on BioPortfolio]

Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based o...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Antibe Therapeutics Inc." on BioPortfolio

We have published hundreds of Antibe Therapeutics Inc. news stories on BioPortfolio along with dozens of Antibe Therapeutics Inc. Clinical Trials and PubMed Articles about Antibe Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Antibe Therapeutics Inc. Companies in our database. You can also find out about relevant Antibe Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record